TASLY(SH:600535) 2 1 Shi Ji Jing Ji Bao Dao·2025-06-12 04:49Core Insights - The 10th Smart Pharmaceutical Academic Industry Conference was held in Tianjin, showcasing advancements in traditional Chinese medicine and smart manufacturing [1][3] - Tianshili Pharmaceutical Group played a significant role in the conference, presenting its strategic layout and technological breakthroughs in smart manufacturing [3][10] - The conference emphasized the importance of digital transformation in the pharmaceutical industry, with Tianshili leading initiatives to establish industry standards [3][10] Group 1: Conference Highlights - The conference gathered over 300 industry elites and top experts, including Academician Zhang Boli, to discuss the future of smart pharmaceuticals [1] - Tianshili's Chairman Zhou Hui and other executives presented reports on the company's advancements in digital quality systems and smart manufacturing technologies [3][5] - The event featured the launch of the "Pharmaceutical Industry Digital Action Tianjin Initiative," highlighting Tianshili's leadership in industry transformation [3][10] Group 2: Technological Innovations - Tianshili's digital quality system integrates blockchain traceability, AI process optimization, and smart equipment control, enhancing product quality consistency to international standards [5][12] - The company developed a fifth-generation high-speed jet granulator, addressing production challenges and significantly improving efficiency [7][8] - Tianshili's smart production line automates the entire process from raw material input to finished product packaging, showcasing its commitment to technological advancement [8][12] Group 3: Research and Development - Tianshili has established a comprehensive R&D model that integrates modern Chinese medicine, biopharmaceuticals, and precision medicine, leading to the launch of new products [12] - The company has completed three new drug registration applications and seven clinical research applications in the past year, with a pipeline of 98 products, including 33 innovative drugs [10][12] - Tianshili's commitment to digital transformation and R&D innovation positions it as a leader in modernizing the traditional Chinese medicine industry [12][13] Group 4: Future Outlook - The release of the Tianjin Initiative marks a new phase of collaborative innovation in the pharmaceutical industry's digital transformation [13] - Tianshili aims to empower the health of China through its "Digital Chinese Medicine + Innovative Chinese Medicine" strategy, emphasizing the necessity of digital transformation for the industry [13] - The company is poised to continue leading the modernization of traditional Chinese medicine through technological advancements and patient-centered approaches [13]